More than 40 large volume wearable injectors are presently available / under development for the administration of drugs

The convenience of subcutaneous route of drug administration and the reformulation of intravenous drugs, reaching patent expiry, for SC delivery has provided an impetus to the development of large volume wearable injectors. In fact, according to the experts in this field, the industry is putting in significant efforts to develop efficient and effective drug-device combinations to deliver large volumes of drugs over a convenient period of time.

 

To order this 540+ page report, which features 175+ figures and 200+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/large-volume-wearable-injectors/238.html

Key Inclusions

• An overview of current market landscape of the large volume wearable injectors available for delivery of insulin and non-insulin drugs, providing information on status of development and device specifications, such as type of device (patch pump / injector and infusion pump / injector), type of dose administered (basal, bolus and others), route of administration (subcutaneous and others), mode of injection (needle, needle / cannula and needle / catheter), storage capacity of the device, actuation mechanism (electromechanical, rotary pump, cell / expanded battery, pressurized gas, osmotic pressure and others), usability (disposable and reusable), availability of prefilled drug reservoir and availability of device connectivity. The report also features additional information on availability of prefilled insulin cartridges, availability of continuous glucose monitoring / blood glucose monitoring (CGM / BGM) systems, availability of Automated Insulin Delivery feature and type of remote control features (control within device / personal diabetes manager (PDM) / smartphone) in the insulin delivery devices.
• A detailed competitiveness analysis of large volume wearable injectors based on various relevant parameters, such as supplier power (based on the experience / expertise of the developer) and product specifications (type of device, type of dose, storage capacity of the device, usability, route of administration, connectivity and availability of a continuous glucose monitoring / blood glucose monitoring (CGM / BGM) systems (in case of insulin devices).
• Elaborate profiles of the prominent companies that develop large volume wearable injectors. Each company profile features a brief overview of the company, its financial information (if available), information on its product portfolio, recent developments and an informed future outlook. Additionally, the report includes tabulated profiles of wearable drug device combination products.
• An analysis of the partnerships that have been inked by the stakeholders in this domain, during the period between 2015 and 2020, covering acquisitions, product development agreements, product integration agreements, technology integration agreements, distribution and supply agreements, commercialization agreements, clinical trial agreements, licensing agreements, manufacturing agreements,  service agreements, and other relevant types of deals.

 

The USD 2.7 billion and USD 600 million (by 2030) financial opportunity within the large volume wearable injectors market for the delivery of insulin  and of non-insulin drugs, respectively, has been analyzed across the following segments:

• • Type of Device
• Patch Pump / Injectors
• Infusion Pump / Injectors

 

• • Product Usability
• Disposable
• Re-usable

 

• • Therapeutic Area (for non-insulin drugs)
• Neurological Disorders
• Cardiovascular Disorders
• Oncological Disorders
• Infectious Disorders

 

• Key geographical regions
• North America
• Europe
• Asia Pacific

 

The report Large Volume Wearable Injectors Market (5th Edition), 2020-2030: Focus on Bolus, Basal and Continuous Delivery Devices.” features the following companies, which we identified to be key players in this domain:

• Becton Dickinson
• Bespak (subsidiary of Consort Medical)
• CeQur
• Debiotech
• Eli Lilly
• Enable Injections
• Insulet
• Medtronic
• PharmaSens
• Roche
• SOOIL Development
• Sonceboz
• Sensile Medical (acquired by Gerresheimer)
• SteadyMed Therapeutics (acquired by United Therapeutics)
• Tandem Diabetes Care
• Weibel CDS (acquired by SHL Medical)
• West Pharmaceutical Services

 

 

 

 

Table of Contents

 

1. Preface

2. Executive Summary

3. Introduction
 

4. Large Volume Wearable Injectors: Current Market Landscape
 

5. Product Competitiveness Analysis
 

6. Large Volume Wearable Injectors: Key Players
 

7. Drug Device Combinations: Tabulated Profiles
 

8. Partnerships and Collaborations
 

9. Key Acquisition Targets
 

10. Patent Analysis
 

11. Large Volume Wearable Injectors: Likely Drug Candidates

 

12. Emerging Trends on Social Media

 

13. Clinical Trial Analysis

 

14. Case Study: Role of CMOs in Device Development and Manufacturing

 

15. Regulatory and Reimbursement Landscape for Medical Devices

 

16. Market Sizing and Opportunity Analysis

 

17. SWOT Analysis

 

18. Executive Insights

 

19. Appendix 1: Tabulated Data

 

20. Appendix 2: List of Companies and Organizations

 

To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/large-volume-wearable-injectors-market-4th-edition-2018-2030/238.html

 

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

[email protected]